Cottereau A, et al. - Since high total metabolic tumor volume (TMTV) measured on 18F-FDG PET/CT before R-CHOP was shown to be significantly correlated with inferior progression-free survival (PFS) and overall survival (OS) in patients with diffuse large B-cell lymphoma, researchers examined the prognostic impact of baseline TMTV together with biological profile. Using the 41% SUVmax method, TMTV was computed on baseline PET/CT. According to results, clinical features were comparable to the overall population. Findings revealed that 4y-PFS was 73% and 4y-OS was 85% after a median 5 years follow-up. TMTV measured on baseline PET/CT is DLBCL's strongest result prognosticator, even in patients following R-CHOP response. In patients receiving either placebo or lenalidomide, high TMTV at baseline was significantly linked to inferior PFS and OS.